Articles On Impression Healthcare (ASX:IHL)

The medicinal cannabis and psychedelic clinical development company has achieved a significant milestone for both the company and sector with positive results from a trial using its novel cannabinoid combination in patients with  obstructiv...

Highlights Incannex’s preliminary assessment of proof-of-concept trial data has indicated efficacy and good safety characteristics of IHL-42X. The data highlighted substantial reduction in AHI, meeting the expectations. Average of low...

Incannex Healthcare (ASX: IHL) has completed a preliminary analysis of data from a phase 2 proof-of-concept clinical trial investigating novel cannabinoid combination product IHL-42X for the treatment of obstructive sleep apnoea (OSA). Cond...

Incannex Healthcare (IHL) sees a substantial reduction in obstructive sleep apnoea during clinical trials The clinical-stage pharmaceutical company completed a preliminary analysis of data from its clinical trial investigating its novel ca...

Like my brave suburb near the airport, the ASX 200 is sinking on Tuesday. Only, the XJO is down around half a per cent, while we haven’t been this wet since 1820. It’s all about perspective. At 3.15pm (Sydenham time) the ASX Emerging Compan...

As energy continues to steal the market spotlight, Incannex Healthcare Ltd [ASX:IHL] is enduring a mixed day of trading. The post Incannex Shares Swing Strongly as It Announces Agreement with Monash University appeared first on Money Mornin...

Clinical-stage medicinal cannabis and psychedelic pharmaceutical company Incannex Healthcare (ASX: IHL) has secured a licence agreement with Victoria’s Monash University to develop a novel treatment for anxiety which combines virtual realit...

Incannex Healthcare (IHL) executes a license agreement with Monash University to develop an anxiety treatment combining virtual reality (VR) and psychedelics The new treatment is for severe anxiety disorders and uses an exposure-based appr...

The ASX 200 Health Index (XHJ) is trading lower by 0.30% at the time of writing, compared to the broader index which is up by 0.90%. Regenerative medicine company, Avita Medical (ASX:AVH), has been awarded a purchasing contract from Premier...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Clinical-stage medical cannabis and psychedelic pharmaceutical company Incannex Healthcare (ASX: IHL) has made its debut on the US-based Nasdaq Global Market using American Depositary Shares (ADS) to represent its ordinary shares under the...

The bell has rung on Incannex’s much anticipated Nasdaq listing with the company hoping to attract keen medical cannabis investors as it pursues North American growth. Medical cannabis and psychedelic clinical development company Incannex H...

Melbourne-based medicinal cannabis product developer Incannex (ASX: IHL) has officially landed on the US stock exchange Nasdaq, hoping its dual listing will attract an expanded pool of investors. The company, which also specialises in psyc...

Medicinal cannabis developer, Incannex Healthcare (IHL) debuts on the Nasdaq trading under ticker code IXHL It follows the US Securities and Exchange Commission declaring IHL’s registration statement on Form 20-F effective, and formal appr...

With a share price that has risen ~65% in the past year, a recent merger with CDA Health and turning a strong profit, Cronos is leading its ASX peers. Medicinal cannabis company Cronos Australia (ASX:CAU) has reported a massive 1100% increa...

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has spent the December quarter pursuing the development of its lead drugs and therapies for patients with unmet medical needs. The company kicked off the perio...

ASX cannabis shares were a mixed bag in 2021 with the broad sector showing weakness across the entire year. Several of the majors underperformed, while key players continued to sprout through. Checking the trade quotes for cannabis stocks...

Shares in medicinal cannabis company Incannex Healthcare Ltd (ASX: IHL) chugged along nicely on Tuesday to start off the ney year 12% higher at 70 cents. It was a busy time in 2021 for the company, filled with plenty of upside and downsid...

Shares in the ASX cannabis sector have had another difficult time in December, as most majors come in well behind the benchmark. Investors are still crowding out of positions in ASX cannabis stocks at a fairly sturdy pace since our last u...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The Australian medicinal cannabis market has seen strong growth in 2021, with revenue from product sales estimated at $230 million. And medical cannabis prescriptions are at an all-time high. The TGA said 13,666 Australian patients were app...

With Phase 2 dosing complete, IHL now prepares to file a pre-IND meeting application with the US Food & Drug Administration (FDA). Medcan and psychedelic clinical development company Incannex Healthcare (ASX:IHL) has flagged its latest...

Participants in Incannex Healthcare’s (IHL) phase two, proof-of-concept clinical study testing a new cannabis combination medication have finished their dosing The cannabinoid combination product, IHL-42X, is hoped to treat obstructive sle...

The ASX 200 Health Index (XHJ) is trading higher by 0.92% at the time of writing, compared to the broader index which is down by 0.22%. Cannabis-based medtech company, Emyria Limited (ASX:EMD), has signed an agreement with Seattle-based Cyd...

Cannabinoid and psychedelics biotech Incannex Healthcare (ASX: IHL) has completed dosing of participants in its phase two proof-of-concept clinical trial of IHL-42X for the treatment of obstructive sleep apnoea. The company has also commenc...

The Incannex Healthcare Ltd (ASX: IHL) share price is in the red today after a company update on its potential NASDAQ listing. Shares in the medicinal cannabis company were swapping hands at 47.5 cents at the time of writing, down 5%. Le...

Incannex Healthcare (ASX: IHL) has announced it is targeting a public offering and Nasdaq listing of American Depositary Shares in the United States next month. The company revealed today it has adequately addressed comments from the US Sec...

Medicinal cannabis business Incannex Healthcare (IHL) is finalising its US Public Offering and getting ready to list on the NASDAQ The ASX-lister believes it will open the offering of American Depositary Shares (ADSs) in January, with each...

The ASX 200 Health Index (XHJ) is trading flat at the time of writing, compared to the broader index which is up by 0.47%. In an announcement this week, Australian medicines regulator the TGA ruled that psychedelic drugs cannot be used to t...

ASX cannabis shares had a difficult month in November, with most majors finishing deep in the red. Scrolling through the extensive list of Aussie cannabis stocks, it’s abundantly clear that the sector experienced a wide sell-off. This coin...

The S&P/ASX 200 Health Care index (ASX: XHJ) pared its October gains in November. The index went from 2.62% up in October to a slight 0.11% fall over November to 46,299 points. However, ASX healthcare shares did outperform the S&P...

Shares in medicinal cannabis company Incannex Healthcare Ltd (ASX: IHL) are edging lower and now trade at 57.5 cents. The Incannex Healthcare share price opened at 60 cents before reversing within minutes to bounce off a low of 56.5 cent...

Instead of a chocolate advent calendar this year, Californians can get their hands on a cannabis calendar with edibles, prerolls, grams of flower and four days of cannabis accessories. “We’ve seen the success of unique advent calendars in o...

ASX cannabis shares were nothing short of a mixed bag last month. Several names did well but a large body of shares missed the benchmark completely. For some context, the S&P/ASX 200 Health Care index (ASX: XHJ) regained steam over th...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today, we hear from Paul Hart, executive director of Canary Capital.   Biotech is hot right now Hart sai...

Highlights  Despite going through a rough patch, few ASX shares have gained over 400% from the prior year. IHL’s revenue increased to AU$1.89 million from AU$604,884 in FY2020. IHL, CXL, ACW, NVX and LTR delivered 213%, 431%, 567%, 51...

Incannex Healthcare (IHL) spikes on the ASX today after landing important regulatory approvals to trial a psychedelic-based treatment for severe anxiety Alongside researchers from Monash University, Incannex’s trial will test the safety an...

Psychedelic and cannabinoid biotech company Incannex Healthcare (ASX: IHL) has received ethics approval to proceed with a phase 2a psilocybin-assisted psychotherapy clinical trial for patients with crippling generalised anxiety disorder. Ap...

The ASX 200 Health Index (XHJ) is up by 1.2% at the time of writing, compared to the broader index which is higher by 1%. Truscreen Group (ASX:TRU) was the best health stock performer, up by 38% after reporting key milestones including the...

Incannex Healthcare (IHL) has engaged Procaps S.A. to manufacture its soft-gel capsules in preparation for clinical trials The agreement between IHL and Procaps is effective immediately and will see Procaps manufacture the IHL-42X soft gel...

The Incannex Healthcare Ltd (ASX: IHL) share price is gaining ground in early trade today and is currently changing hands at 37.5 cents apiece. At one point today, shares in the medicinal cannabis company were trading 6% higher on the pre...

Cannabinoid and psychedelic biotech company Incannex Healthcare (ASX: IHL) has engaged pharmaceuticals manufacturer Procaps SA to develop a soft gel capsule form of its IHL-42X cannabinoid drug for the treatment of obstructive sleep apnoea....

Turn on, tune in and don’t drop out. The push to develop psychedelic drugs is gaining momentum, but not quite in the way the 1960s counter-culture figure Dr Timothy Leary intended. The late Harvard psychologist strongly advocated the use of...

Clinical-stage cannabinoid and psychedelics medicine developer Incannex Healthcare (ASX: IHL) has announced it has raised almost $18 million via the completion of option exercises. A total of 118 million option securities were exercised at...

As we make our way through the first half of FY22, equity markets have begun to shake up somewhat in the last few weeks. The benchmark S&P/ASX 200 Index (ASX: XJO) has slumped almost 4.5% into the red over the last month, back to its...

The Incannex Healthcare Ltd (ASX: IHL) share price has taken a beating over the past four weeks, having come off its all-time high of 44.5 cents on 2 September. Prior to this, Incannex shares rallied from mid-August until this point. So, w...

The Incannex Healthcare Ltd (ASX: IHL) share price has been a winner on the ASX over the last few weeks and posted outsized gains. Whereas the S&P/ASX 200 Index (ASX: XJO) has slipped 2.7% into the red over the past month, Incannex sh...

The Incannex Healthcare Ltd (ASX: IHL) share price is having a year to remember. At the time of writing, shares in the company are up 170% in 2021 and 3.7% today to 42 cents each. It’s an impressive feat with many factors behind it. Let’s...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Virginia is the latest US state to legalise marijuana and they’re celebrating with the first annual CannaFest VA cannabis trade show on September 19. The event will feature a concert, and a custom car and motorcycle exhibition but no, you c...